leukemia

[Wugen, Inc.] Wugen, Inc. announced that the first patient has been dosed in a Phase I/II trial of WU-CART-007 for the treatment of relapsed or refractory T cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma.

[Oryzon Genomics, S.A.] Oryzon Genomics, S.A. announced that it has received notification from the US FDA that its Investigational New Drug application (IND) for iadademstat is now approved to initiate a Phase Ib clinical trial in patients with relapsed/refractory AML harboring a FMS-like tyrosine kinase mutation (FLT3mut+ ).

[Nature Medicine] Researchers investigated the role of the intestinal microbiome onvarious outcomes in a multicenter study of patients with B cell lymphoma and leukemia.

[Blood Cancer Discovery] Researchers demonstrated that BCOR and BCORL1 mutations in leukemia unlinked PRC1.1 repressive function from target genes, resulting in epigenetic reprogramming and activation of aberrant cell signaling programs that mediated treatment resistance.

[Cell Reports] Investigators established that identification of the comprehensive miRNA targetome within primary cells enabled discovery of genes and molecular networks underpinning stemness properties of normal and leukemic cells.

[Cancer Research] A novel T cell receptor (TCR)-associated non-canonical function of AGO2 represented, in addition to TCL1A-mediated TCR signal augmentation, another enhancer mechanism of an important deregulated growth pathway in T cell prolymphocytic leukemia.